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Abstract: The emergence of nanotechnology has had a profound effect on many areas of 
healthcare and scientiﬁ  c research. Having grown exponentially, the focus of nanotechnology 
has been on engineering diversiﬁ  ed novel applications that even go beyond therapeutic activity; 
nanotechnology also offers the ability to detect diseases, such as cancer, much earlier than ever 
imaginable. Often, patients diagnosed with breast, lung, colon, prostate, and ovarian cancer 
have hidden or overt metastatic colonies. With the advent of diagnostic nanotechnology, these 
numbers are expected to greatly diminish. This review provides a brief description of nanopar-
ticle (liposome, quantum dot, and dendrimer)-mediated cancer therapy in the last decade with 
an emphasis on the development and use of dendrimers in cancer therapeutics.
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Introduction
Nanoscience is an emerging ﬁ  eld that deals with interactions between molecules, cells 
and engineered substances such as molecular fragments, atoms and molecules. In terms 
of size constraints, the National Nanotechnology Initiative (NNI) deﬁ  nes nanotechnology 
in dimensions of roughly 1 to 100 nanometers (nm),1 but in boarder range it can be 
extended up to 1000 nm. Particles that fall within this range appear to be optimal for 
achieving a number of important tasks as nano-carriers, including the alteration of a 
drug’s reactivity, strength, electrical properties, and ultimately, its behavior in vivo. 
There is great interest in developing new nanodelivery systems for drugs that are already 
on the market, especially cancer therapeutics. Ideally, nanodelivery systems will allow 
for more speciﬁ  c targeting of the drug, thereby improving efﬁ  cacy and minimizing side 
effects. By using nanotechnology in drug design and delivery, researchers are trying 
to push nanomedicine to be able to deliver the drug to the targeted tissue, release the 
drug at a controlled rate, be a biodegradable drug delivery system, and to be able to 
escape from degradation processes of the body.
Cancer is a disease that affects millions of Americans in all age groups and both 
sexes. According to the American Cancer Society, the probability of developing 
cancer during one’s lifetime is one in two for men and one in three women.2 Most of 
the current chemotherapeutic agents on the market are low molecular weight agents 
with high pharmacokinetic volume of distribution both of which contribute to their 
cytotoxicity. Moreover, the low molecular weight of these chemicals makes them easily 
excreted, hence a higher concentration is ultimately required, and consequently a higher 
toxicity is unavoidable. Their low therapeutic index does not contribute favorably to 
this dilemma, as the needed concentration for the effective treatment must always be 
reached, but unfortunately the therapeutic levels are often exceeded. Additionally, these 
drugs when administrated alone, lack speciﬁ  city and cause signiﬁ  cant damage to non-
cancerous tissues. This results in serious, unwanted side effects such as bone marrow 
suppression, hair loss (alopecia), and the sloughing of the gut epithelial cells.3International Journal of Nanomedicine 2009:4 2
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Most chemotherapeutic agents have poor solubility and 
low bioavailability, and are formulated with toxic solvents.4 
Thus, the use of nanocarriers allow for the preparation of low 
water soluble cancer medications in solid or liquid formula-
tions. Doxil and Abraxane are the two well known US Food 
and Drug Administration (FDA)-approved nanoformulations 
currently available on market for cancer treatment. Doxil5–7 
is a long circulating liposomal formulation of doxorubicin, 
which has shown signiﬁ  cant improvements over its counter-
part, free doxorubicin. The other FDA-approved nanomedi-
cine, Abraxane® (Abraxis Bioscience, Los Angeles, CA), 
a treatment for metastatic breast cancer, is an albumin-
bound nanoparticle formulation of paclitaxel in the ﬁ  eld of 
nanotechnology mediated cancer therapy.8–10 Abraxane® for 
injectable suspension evades the hypersensitivity reaction 
associated with Cremophor EL, the traditionally used solvent 
for paclitaxel. This nanoparticle has a size around 100 nm 
and offers the ability to convert insoluble or poorly soluble 
drugs, avoiding the need for toxic organic solvents.
Having sprouted from a single concept some thirty years 
ago, nanotechnology has given rise to nanomedicine, among 
other applications including those associated with physics, 
biochemistry, and biotechnology, for creating molecular 
devices able to facilitate therapeutic and diagnostic proce-
dures on the nanoscale. Thus, applications of nanotechnology 
have generated immense interest over past decade in various 
ﬁ  elds for diverse applications. This review will discuss the 
nanotechnological research that has been conducted regarding 
liposomes, quantum dots (QDs), and especially dendrimers 
in anticancer therapeutics over the past decade.
Liposomes
Liposomes are small lipid vesicles within the range of 50 to 
1000 nm.11,12 Because of their unique advantages over tradi-
tional drug therapy, including their ability to protect the drugs 
from degradation, targeting the drug to the site of action and 
reducing the toxicity and side effects of such drugs, liposomes 
have been studied extensively as drug carriers particularly 
for cancer therapy.13 Depending upon their size and number 
of bilayers, liposomes can be classiﬁ  ed into three categories: 
multi-lamellar vesicles (MLV); large uni-lamellar vesicles 
(LUV); and small uni-lamellar vesicles (SUV). Liposomes 
can be classiﬁ  ed in terms of composition and mechanism of 
intracellular delivery into ﬁ  ve types: conventional liposomes 
(CL), pH-sensitive liposomes, cationic liposomes, immuno-
liposomes, and long-circulating liposomes (LCL). The major 
problems associated with liposomes are their stability, poor 
batch to batch reproducibility, difﬁ  culty in sterilization, and 
low drug loading capacity. Although liposomes have been 
extensively studied for last few decades, the only efﬁ  cient 
nanoformulation available in the market is Doxil® (ALZA, 
Moutain View, CA).
Quantum dots
Semiconductor QDs are rapidly emerging as popular lumines-
cence probes for many biological and biomedical applications 
owing to their extremely small size (approximately 10 nm in 
diameter), high photostability, tunable optical properties, and 
multimodality.14–18 Such inorganic–organic composite nano-
materials have shown extreme efﬁ  ciency in cancer diagnosis 
in vivo, with their small size which facilitates unimpeded 
systemic circulation and attached targeting molecules, allow-
ing for speciﬁ  c ‘honing in’ at neoplastic sites.19–22 Similar to 
other nanoparticles, QDs can be modiﬁ  ed via conjugation 
of various surface molecules for targeted delivery.23,24 QDs 
also provide sufﬁ  cient surface area to attach therapeutic 
agents for simultaneous drug delivery and in vivo imaging25 
as well as for tissue engineering.26 In vivo cancer targeting 
and imaging in living animals by QDs was ﬁ  rst demonstrated 
by Gao and colleagues,19 where both subcutaneous injection 
of QD-tagged prostate cancer cells and systemic injection of 
multifunctional QD probes were used to achieve sensitive and 
multicolor ﬂ  uorescence imaging of cancer cells. In a recent a 
study, Bagalkot and colleagues27 used QD–apatamer (Apt)–
doxorubicin (Dox) conjugate for targeted cancer therapy, 
imaging, and sensing. It was shown that this multifunctional 
nanoparticle system can deliver doxorubicin to the targeted 
prostate cancer cells and sense the delivery of doxorubicin 
by activating the ﬂ  uorescence of QD, while allowing for 
simultaneous imaging of the cancer cells.
Though most of the major challenges associated with 
QD to make less toxic optical probes for biological applica-
tions have been overcome using different coating materials, 
under some conditions QDs can become cytotoxic.28 It was 
discovered that CdSe particles may leak cytotoxic cadmium 
ions after long-term exposure to ultraviolet (UV) light, while 
CdTe particles produce reactive oxygen species due to the 
loss of their protective coating after long-term circulation. 
In both cases, cytotoxicity and cell death were recorded.29–32 
Research is ongoing to ﬁ  nd suitable biocompatible and stable 
QD coatings. Nevertheless, QDs also found its application in 
the near infrared (NIR) imaging (700–1000 nm).33 The use 
of NIR-QDs can maximize the depth of tissue penetration, 
allowing for more accurate and sensitive detection of photons 
in vivo, which is limited by absorption and light scattering 
in conventional imaging, allowing for more accurate and International Journal of Nanomedicine 2009:4 3
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sensitive detection of photons in vivo. NIR-QD also may 
be a superior alternative because they can circumvent the 
problem of auto-ﬂ  uorescence which is often associated 
with optical imaging of naturally-occurring compounds in 
animal tissue. Thus, these QDs have tremendous potential 
for in vivo imaging, and have already been used in various 
in vivo studies, including lymphatic mapping in animal 
models.34,35
Dendrimers
Dendrimers are a unique class of repeatedly branched poly-
meric macromolecules with numerous arms extending from 
a center, resulting in a nearly-perfect three-dimensional geo-
metric pattern. Dendrimers can be synthesized via two major 
strategies: a) divergent methods and b) convergent methods, 
which differ in their direction of synthesis; either outward 
from the core or inwardly toward the core, respectively. 
Divergent methods were ﬁ  rst introduced by Tomalia36 in 
the 1980’s, where his group synthesized three-dimensional 
polyamindoamine (PAMAM) dendrimers by the growth of 
branches extending radially from a core site to the periph-
ery.37 Furthermore, PAMAM dendrimers contain tertiary 
amines and amide linkages which allow for the binding of 
numerous targeting and guest molecules.
Hawker and Frechet are well known for having established 
the convergent strategies for the synthesis of dendrimers.38 In 
convergent methods, dendrimer surfaces are ﬁ  rst synthesized 
by gradually linking surface unit monomers together. When 
the growing surface wedges are large enough, several are 
attached to a suitable core to give a complete dendrimer. 
Polypropylenemine (PPI) and polyaryl ethers dendrimers 
are synthesized by using this convergent method.
Dendrimers have three components: an initiator core, 
branches, and terminal functional groups. The initiator core 
is in the heart of the molecule, and branches extend outward 
from it. The monomers attached to the core (G0), are called 
ﬁ  rst generation monomers (G1) and two second generation 
monomers (G2) are attached to the each ﬁ  rst generation mono-
mers. Successive generations will form in this same manner, 
being two monomers attached to the monomer from the 
previous generation (Figure 1). The molecular weight of the 
dendrimer nearly doubles with each additional generation.39 
Furthermore, terminal groups can be modiﬁ  ed to obtain both a 
charged, and hydrophilic or lipophilic function for the desired 
biological and drug delivery application.40
The advantage of dendrimers is that they can be synthe-
sized and designed for speciﬁ  c applications. They are ideal 
drug delivery systems due to their feasible topology, func-
tionality and dimensions; and also, their size is very close to 
various important biological polymers and assemblies such 
as DNA and proteins which are physiologically ideal.41
Many of the properties of dendrimers include:42
1.  Nanoscale sizes that have similar dimensions to important 
bio-building blocks, eg, proteins, DNA.
2.  Numbers of terminal surface groups (Z) suitable for bio-
conjugation of drugs, signaling groups, targeting moieties 
or biocompatibility groups.
3.  Surfaces that may be designed with functional groups 
to augment or resist trans-cellular, epithelial or vascular 
biopermeability.
4.  An interior void space may be used to encapsulate small 
molecule drugs, metals, or imaging moieties. Encapsu-
lating in that void space reduces the drug toxicity and 
facilitates controlled release.
5.  Positive biocompatibility patterns that are associated 
with lower generation anionic or neutral polar terminal 
surface groups as compared to higher generation neutral 
apolar and cationic surface groups.
Core molecule
Surface molecule
Generation: G0 G1
1.4 nm 1.9 nm
G2
2.6 nm
G3
3.6 nm
G4
4.4 nm Diameter:
Figure 1 Graphical representation of dendrimers from core to generation G = 4, showing the linear increase in diameter.International Journal of Nanomedicine 2009:4 4
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6.  Non- or low-immunogenicity associated with most 
dendrimer surfaces modiﬁ  ed with small functional groups 
or polyethylene glycol (PEG).
7.  Surface groups that can be modiﬁ  ed to optimize biodis-
tribution; receptor mediated targeting, therapy dosage or 
controlled release of drug from the interior space.
8.  Ability to arrange excretion mode from body, as a func-
tion of nanoscale diameter.
Dendrimer and anticancer drug delivery
One of the major applications of dendrimers is as a delivery 
vehicle for various anticancer drugs. The structure and 
tunable surface functionality of dendrimers allows for the 
encapsulation/conjugation of multiple entities, either in 
the core or on the surface, rendering them ideal carriers for 
various anticancer drugs. There are numerous examples of 
dendrimer mediated targeted drug delivery.
In 2002, Jesus and colleagues43 had explored the pos-
sibility of a 2, 2-bis (hydroxymethyl) propanoic acid based 
dendritic scaffold as a delivery carrier for doxorubicin in vitro 
and in vivo. This dendritic nanoformulation, which contains 
doxorubicin covalently bound through a hydrazone linkage to 
a high molecular weight 3-arm polyethylene oxide; exhibits 
reduced cytotoxicity in vitro. However, in vivo biodistribu-
tion experiments showed minimal accumulation of the DOX-
dendrimer conjugate in vital organs, including the liver and 
heart, and increased half-life of doxorubicin compared to the 
free drug. Thus, it was hypothesized that proper choices of 
nanocarrier systems can increase the circulation half-life to 
effectively exploit the enhanced permeation retention (EPR) 
effect phenomenon and thus have tremendous potential to 
increase the efﬁ  cacy of the drug to a greater extent.
In an attempt to improve the efﬁ  cacy of doxorubicin, Lai 
and colleagues44 utilize photochemical internalization (PCI) 
technology for site-speciﬁ  c delivery of membrane imperme-
able macromolecules from endocytic vesicles into the cyto-
sol. PCI technology has been demonstrated to successfully 
enhance the cytotoxicity of cancerous tissue by destroying 
the cytoplasmic membrane and facilitating the release of 
macromolecules entrapped in cytoplasmic vesicles. PAMAM 
dendrimers were conjugated to doxorubicin through the 
amide (PAMAM–amide–DOX) or the hydrazone (PAMAM–
hyd–DOX) bonds. Two different PCI strategies referred to 
as ‘light after’, and ‘light before’, where exposure to light 
is either after or before treatment with doxorubicin respec-
tively, were applied to evaluate the cytotoxic effects of these 
doxorubicin PAMAM conjugates against Ca9-22, gingival 
carcinoma, cells. It was observed that only the ‘light after’ PCI 
treatment signiﬁ  cantly increased the nuclear accumulation of 
doxorubicin from the PAMAM-hyd-DOX conjugates and thus 
exhibited higher cytotoxicity probably due to the synergistic 
effects. Both PCI strategies failed to improve the cytotoxicity 
of PAMAM-amide-DOX conjugates.
Many investigators have also explored the feasibility of   
cisplatin incorporation in dendrimers. One of the early exam-
ples is PAMAM dendrimer generation 3.5 conjugated to 
cisplation through the sodium carboxylate surface giving a 
dendrimer–platinate (dendrimer–Pt; 20–25 wt% platinum), 
which resulted in a fairly water soluble nanoformulation 
with the ability to release cisplatin slowly in vitro.45 It was 
observed that this formulation showed superior activity over 
cisplatin when injected i.p. into mice bearing B16F10 tumor 
cells, whereas the dendrimer-Pt and cisplatin were equi-active 
i.p. against i.p. L1210. Also, when administered i.v. to treat a 
palpable s.c. B16F10 melanoma, the dendrimer-Pt displayed 
additional antitumor activity whereas cisplatin was inactive.
Zhou and colleagues46 synthesized poly (amide-amine) 
based dendrimers with a cyclic core and four direction 
branches using the method referred to as ‘time-sequenced 
propagation technique’. Using this technique, they successfully 
synthesized dendrimers from generation 0.5 to generation 5.5. 
Further, dendrimers were then reacted with 1-bromoacetyl-5-
ﬂ  uorouracil to form dendrimer–5FU conjugates. In vitro release 
kinetics in PBS revealed that the release of 5FU depends on 
the generation of the dendrimer used for the conjugation, and 
indicated that such a dendritic polymer could be a promising 
carrier for the controlled release of antitumor drugs.
PEGylated dendrimers are one of the sub-classes of 
dendrimers that attract numerous scientists due to its pro-
longed blood circulation time, lower level of toxicity and 
relatively lower accumulation in different organs. Also, in 
vivo experiments show a signiﬁ  cantly higher accumulation in 
the tumor tissues due to the EPR effect.47 PEG-dendrimers are 
generally synthesized by the conjugation of PEG or polyeth-
ylene oxide (PEO) chains to a multifunctional dendritic chain. 
A 2006 study by Lee and colleagues48 showed the feasibility 
of polyester-based dendrimer–PEO–doxorubicin conjugate 
to substantially inhibit the progression of DOX-insensitive 
C-26 tumor subcutaneously implanted in BALB/c mice. 
This dendrimer–PEO–doxorubicin conjugate also showed 
the ability to eliminate the tumors at certain doses and was 
found to be more or less the same as compared to an equal 
amount of Doxil, which is currently available for liposome 
formulation of DOX.
Additionally, Bhadra and colleagues,49 used PEGylated 
PAMAM dendrimers for the incorporation of 5FU. Thus, as International Journal of Nanomedicine 2009:4 5
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anticipated, it was observed that this is formulation is suitable 
for prolonged delivery of anticancer drugs by in vitro and 
blood-level studies in albino rats, without producing any 
signiﬁ  cant hematological disturbances. PEGylation contrib-
uted an additional advantage to the dendrimer formulation 
by reducing drug leakage and hemolytic toxicity. This, in 
turn, could improve drug-loading capacity and stabilize such 
systems in the body.
Dendrimers for targeted delivery
In the last few years there has been a growing interest by 
various scientists to use dendrimers for targeted delivery 
especially in cancer therapeutics. The multifunctional nature 
of the dendritic network makes it easier for researchers 
to incorporate both the drug and the targeting moieties 
simultaneously, and thus can be used for active targeting. 
Furthermore, passive targeting of tumors can also be achieved 
through PEGylation on the surface of dendrimers. It is well 
established that PEGylated nanoparticles accumulate in the 
tumor tissues due to the EPR effect. On the surface of a 
variety of cancer cells, folate receptors are overexpressed.50 
Folate-modiﬁ  ed dendrimers target these cells via ligand-
receptor recognition. Folic acid targeted dendrimers which 
are covalently conjugated with methotrexate speciﬁ  cally kill 
receptor-expressing cells after the intracellular delivery of the 
drug through receptor-mediated endocyctosis.51 Quintana and 
colleagues52 synthesized an ethylenediamine core PAMAM 
dendrimer of generation 5 which was covalently attached 
to folic acid, ﬂ  uorescein, and methotrexate. This complex 
provided targeting, imaging and intracellular drug delivery 
capabilities with 100-fold decreased cytotoxicity over free 
methotrexate.
The unique architecture of dendrimers allows for mul-
tivalent attachment of imaging probes as well as targeting 
moieties. Thus, it can be also used as highly efficient 
diagnostic tool for cancer imaging. Gadolinium (Gd)-
based magnetic resonance imaging (MRI) contrast agents 
(CAs) can operate using an approximately 100-fold less 
concentration than iodine atoms required for computed 
tomography imaging. They can be targeted to a single site 
which improves the sensitivity of imaging. Furthermore, the 
size of the complex prevents leakage from the bloodstream 
into ﬂ  uids in the body, which also improves sensitivity and 
image clarity.53
Dendrimer and carbon nanotube
The utilization of dendrimers as ‘nanotemplates’ for carbon 
nanotube formation in a controlled manner has been a 
growing area of research interest since Choi and his group 
introduced the idea of utilizing PAMAM dendrimers for the 
synthesis of catalytic nanoparticles for single-walled carbon 
nanotube (SWNT). Thus, using this dendritic platform, 
chemical vapor deposition (CVD) nanotubes with a narrow 
diameter distribution between 1 and 2 nm were obtained.54 
Later, in another study by Amama and colleagues, the use 
of fourth-generation PAMAM dendrimers as a platform for 
synthesizing multi-walled carbon nanotubes (MWCNTs) 
with systematically varied diameter distributions and defect 
densities by microwave plasma-enhanced chemical vapor 
deposition was demonstrated. This technique involved the 
utilization Fe2O3 nanoparticles prepared via an interden-
dritic templating mechanism involving Fe3+ ions and an 
amine-terminated dendrimer. The diameter distribution and 
quality of MWCNTs can be manipulated judiciously by 
varying the concentration of the catalyst solution and the 
calcination temperature.55 Alternatively, Pan and colleagues 
used PAMAM dendrimers to coat single-walled carbon 
nanotubes (SWCNTs) to reduce cytotoxicity and enhance 
cellular uptake. It was observed that dendrimer coated 
SWCNTs were nontoxic as compared to uncoated SWCNTs. 
Also, the uptake of uncoated SWCNTs in MCF-7 metastatic 
breast cancer cells was found to be signiﬁ  cantly less than 
the dendrimer coated nanotubes, due to increased dendrimer 
mediated endocytosis.56 Therefore, a homogeneous coating of 
a glycodendrimers on SWCNT known to decrease cytotocix-
ity also shows the potential for nanotubes to be utilized as 
protein-binding sensors.57
Nanoparticles and toxicity
Though in recent years there has been a rapid expansion 
in nanoparticle and nanotechnology research in consumer 
products, there is limited information on the possible toxic 
health effects on humans and the environment to date. To 
assess the toxicity in a systematic manner, there is an urgent 
need to investigate the intracellular and in vivo fate of the 
nanoparticulate systems vis-à-vis in surface properties and 
morphology. In an early study by Dunford and colleagues58 
in 1997, it was demonstrated that titanium dioxide/zinc 
oxide nanoparticles used in sunscreen can catalyze oxidative 
damage to DNA in vitro and in cultured human ﬁ  broblasts. 
In 2004, at a nanoscale materials and toxicity conference, 
Nanotox 2004, Vyvvan Howard revealed his initial ﬁ  ndings 
that gold nanoparticles have the ability to move across the 
placenta from mother to fetus when injected into pregnant 
rats.59 There are a few studies that have assessed of toxicity of 
carbon nanotubes. Shvedova and colleagues60 hypothesized International Journal of Nanomedicine 2009:4 6
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that the probable dermal toxicity and morphological changes 
seen were due to accelerated oxidative stress in the skin after 
having been exposed to the SWCNT. Furthermore, in a sepa-
rate study, the same group demonstrated that the exposure to 
unreﬁ  ned SWCNT may lead to increased pulmonary toxicity 
due to oxidative stress.61 Other toxicity studies of carbon 
nanotubes describe the of cause granulomas in rats and mice 
after acute exposure.62 Crystalline silver nanoparticle-related 
cytoxicity in lesioned skin, growing human ﬁ  broblasts, and 
keratinocytes was demonstrated by Lam and colleagues63 and 
Poon and Burd.64 These studies, among others, have begun 
to reveal the toxicity of nanoparticles and will pave the way 
for progression in this ﬁ  eld of study.
Conclusion
The biomedical application of nanoparticles has experienced 
exponential growth in the past few years; however, current 
knowledge regarding the safety of nanocarriers is insufﬁ  cient. 
As these new drug delivery systems are brought to clinical trial 
we will begin to be able to identify any negative side effects 
associated with these compounds. Preliminary and complemen-
tary animal studies should be carried out to identify the risks 
associated with nanoparticle use, with particular attention paid 
to the elimination processes. Furthermore, very little attention 
has been paid to the environmental effects and the potential 
effects on the health of those manufacturing these particles. It is 
reported that only 1% of the total expenditure (US$1.2 billion) 
has been spent on occupational health and safety research of 
nanotechnology.65 Considering the countless potential appli-
cations of nanoparticles in the health sector, particularly in 
cancer research, there is an urgent need for the development 
of safety guidelines by the government. Among the nanopar-
ticulate carriers, dendrimers have tremendous potential in the 
applications involving multifunctional nanoparticulate systems 
combining targeting, imaging, diagnostics and therapy. Thus, 
this multifunctional, unique nanoparticulate carrier has the 
potential to detect diseases, deliver medications, and monitor 
the ability to change the current scenario of cancer research 
and diagnosis in real time.
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